SCHEMBL2705317

SCHEMBL2705317

O=C1CCN(S(=O)(=O)c2ccc(Cl)cc2)c2cccc(F)c21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.58
▸ MEN1 O00255 4/20 0.58
▸ HTR6 P50406 2/20 0.53
▸ MAPT P10636 4/20 0.48
▸ KCNN4 O15554 1/20 0.48
▸ KCNA3 P22001 1/20 0.48
▸ HTR1A P08908 1/20 0.47
▸ DRD4 P21917 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR7 P34969 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ PSEN1 P49768 1/20 0.43
▸ PSEN2 P49810 1/20 0.43
▸ APH1B Q8WW43 1/20 0.43
▸ NCSTN Q92542 1/20 0.43
▸ APH1A Q96BI3 1/20 0.43
▸ PSENEN Q9NZ42 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705507 0.79 KMT2A (0.68) KMT2AMEN1HTR6MAPTKCNN4
SCHEMBL2705025 0.74 PSEN1 (0.56) KMT2AMEN1HTR6MAPTKCNN4
SCHEMBL2703804 0.74 PSEN1 (0.56) KMT2AMEN1HTR6MAPTKCNN4
SCHEMBL5915295 0.74 MEN1 (1.00) KMT2AMEN1MAPTPOLBLMNA
SCHEMBL8229806 0.73 KCNA3 (0.45) KMT2AMEN1MAPTKCNN4KCNA3
SCHEMBL14280953 0.73 KCNA3 (0.45) KMT2AMEN1MAPTKCNN4KCNA3
SCHEMBL2704794 0.73 KMT2A (0.56) KMT2AMEN1HTR6MAPTKCNN4
SCHEMBL2704625 0.72 PSEN1 (0.70) KMT2AMEN1KCNN4KCNA3MMP2
SCHEMBL2702931 0.71 PSEN1 (0.47) KMT2AMEN1MAPTKCNN4KCNA3
SCHEMBL5915297 0.69 KMT2A (0.83) KMT2AMEN1MAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP disclosed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO disclosed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 KMT2A 2307/4885MEN1 2805/4885HTR6 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback